Literature DB >> 14642625

Fibrogenic impact of high serum glucose in chronic hepatitis C.

Vlad Ratziu1, Mona Munteanu, Fréderic Charlotte, Luminita Bonyhay, Thierry Poynard.   

Abstract

BACKGROUND/AIMS: There is considerable variability in the rate of fibrosis progression in patients with chronic hepatitis C, most of which is related to factors so far unknown. We tested the hypothesis that high serum glucose and overweight might contribute to this variability.
METHODS: Seven hundred and ten patients with chronic hepatitis C with a known duration of infection and no hepatitis B virus or human immunodeficiency virus coinfection were studied. Significant fibrosis was defined as bridging fibrosis including cirrhosis. Variables were tested for their association with significant fibrosis.
RESULTS: In univariate analyses both serum glucose and body mass index were associated with fibrosis. In multivariate analyses, age at infection, duration of infection, serum glucose and daily alcohol intake but not body mass index were independently associated with significant fibrosis. Patients with high serum glucose had been contaminated at an older age and had features of the metabolic syndrome, including steatosis more frequently, as well as faster fibrosis progression rates. High serum glucose was associated with intermediate and advanced, but not with early, fibrosis stages. A high serum glucose was associated with a higher relative risk for significant fibrosis than overweight.
CONCLUSIONS: High serum glucose, is an independent co-factor of fibrosis in chronic hepatitis C with a higher pro-fibrogenic impact than overweight.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642625     DOI: 10.1016/s0168-8278(03)00456-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  38 in total

1.  Treatment uptake of patients with chronic hepatitis C: can we expect and do more?

Authors:  Chia-Yen Dai
Journal:  Dig Dis Sci       Date:  2010-12       Impact factor: 3.199

Review 2.  Steatosis in chronic hepatitis C: why does it really matter?

Authors:  T Asselah; L Rubbia-Brandt; P Marcellin; F Negro
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

Review 3.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

4.  Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension.

Authors:  Tsuyoshi Ishikawa; Shogo Shiratsuki; Takashi Matsuda; Takuya Iwamoto; Taro Takami; Koichi Uchida; Shuji Terai; Takahiro Yamasaki; Isao Sakaida
Journal:  J Gastroenterol       Date:  2013-10-05       Impact factor: 7.527

5.  Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.

Authors:  Hesham M Elgouhari; Claudia O Zein; Ibrahim Hanouneh; Ariel E Feldstein; Nizar N Zein
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

Review 6.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

Review 7.  Fat, diabetes, and liver injury in chronic hepatitis C.

Authors:  Vlad Ratziu; Jean-Baptiste Trabut; Thierry Poynard
Journal:  Curr Gastroenterol Rep       Date:  2004-02

8.  Association of hepatitis C virus infection and diabetes.

Authors:  Samir Rouabhia; Rachid Malek; Hocine Bounecer
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

Review 9.  Targeting host factors: a novel rationale for the management of hepatitis C virus.

Authors:  Mahmoud Aboelneen Khattab
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

10.  Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.

Authors:  Francesco Negro
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.